International Journal of Cancer · 1998 · 174 citations · 22 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis ResistanceBcl-2 Family ProteinsChemotherapy ResistanceCytotoxic ChemotherapyBcl-2 Protein ExpressionClonogenic Cell DeathCytotoxicity AssaysGlioma ChemotherapyP16 ExpressionP53 Pathway AlterationsRb Pathway DysregulationRb Pathway Inactivation
Less than 30% of malignant gliomas respond to adjuvant chemotherapy. Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines. Neither wild-type p53 status, nor p53 protein accumulation, nor p21 or MDM-2 levels, nor differential expression of BCL-2 family proteins predicted drug sensitivity, except for an association of BAX with higher beta-lapachone sensitivity in acute cytotoxicity assays. p16 protein expression was associated with high doubling time and chemoresistance. We conclude that some important molecular changes, which are involved in the development of gliomas and attributed a role in regulating vulnerability to apoptosis, may not determine the response to chemotherapy in these tumors.
22
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Thomas G. Graeber, Cynthia Osmanian, Tyler Jacks et al. · Nature · 1996 · 2.3K citations
A novel form of Epstein-Barr virus latency in normal B cells in vivo
E M Miyashita, Bin Yang, K. M. C. Lam et al. · Cell · 1995 · 1.6K citations · Full text
Analysis of the p53 gene and its expression in human glioblastoma cells.
Erwin G. Van Meir, Tetsuro Kikuchi, Mitsuhiro Tada et al. · PubMed · 1994 · 331 citations
Michael Weller, Ursula Malipiero, Adriano Aguzzi et al. · Journal of Clinical Investigation · 1995 · 256 citations · Full text
Medicine, Cancer Biology, Oncology +17